Identification of novel HSP90/isoform selective inhibitors using structure-based drug design. Demonstration of potential utility in treating CNS disorders such as Huntington's disease

Identification of novel HSP90/isoform selective inhibitors using structure-based drug design. Demonstration of potential utility in treating CNS disorders such as Huntington's disease Descriptor: 4-(2,7,7-trimethyl-5-oxo-1,2,3,4,5,6,7,8-octahydro-9H-beta-carbolin-9-yl)benzamide, Heat shock protein HSP 90-alpha Authors: Zuccola, H.J, Ernst, J. Deposit date: 2013-12-13 Release date: 2014-12-24 Last modified: 2024-02-28 Method: X-RAY DIFFRACTION (1.82 Å) Cite: Identification of Novel HSP90 alpha / beta Isoform Selective Inhibitors Using Structure-Based Drug Design. Demonstration of Potential Utility in Treating CNS Disorders such as Huntington's Disease. J.Med.Chem., 57, 2014

基于结构的药物设计方法鉴定新型热休克蛋白90（HSP90）亚型选择性抑制剂，并验证其在治疗亨廷顿病等中枢神经系统（Central Nervous System, CNS）疾病中的潜在应用价值。
化合物标识：4-(2,7,7-三甲基-5-氧代-1,2,3,4,5,6,7,8-八氢-9H-β-咔啉-9-基)苯甲酰胺；靶标蛋白：热休克蛋白HSP 90-α（Heat shock protein HSP 90-alpha）
作者：Zuccola, H.J.、Ernst, J.
提交日期：2013-12-13
发布日期：2014-12-24
最后修改日期：2024-02-28
实验方法：X射线衍射（X-RAY DIFFRACTION），分辨率1.82埃（Å）
引用文献：《基于结构的药物设计方法鉴定新型HSP90 α/β亚型选择性抑制剂并验证其在治疗亨廷顿病等中枢神经系统疾病中的潜在应用价值》，《药物化学杂志》（J.Med.Chem. / Journal of Medicinal Chemistry），57卷，2014年